Figure 1 | Oncogene

Figure 1

From: Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer

Figure 1

Ligand-dependent EGFR activation is not a predictor of sensitivity to anti-EGFR compounds. (a) Western-blot analysis was performed on total lysates from starved IGROV1 and OAW42 cells left untreated or treated for 20 min with EGF alone or together with AG1478. The antibodies used are indicated. β-actin is shown as a control for protein loading. A representative experiment is shown; all experiments were performed in triplicate. (b) IGROV1 and OAW42 cells were exposed to different concentrations of cetuximab for 96 h in medium with fetal calf serum. (c) Dose-response curves of IGROV1 and OAW42 cells treated with Erlotinib or Gefitinib for 72 h. (b, c): Representative growth curves of three independent experiments are shown; each point represents the mean of five independent replicates±s.d. Asterisks indicate a significant difference by two-way analysis of variance.

Back to article page